A well-known example of this is GFJ, which increases plasma levels of several CYP3A4 substrates, including simvastatin, thereby enhancing the risk of adverse effects such as myopathy and rhabdomyolysis [22]. This evidence concerns the gene CYP3A4 and rhabdomyolysis.